Login to Your Account

BMS, AstraZeneca Join Forces in $7B Combo Deal for Amylin

By Catherine Shaffer
Staff Writer

Wednesday, August 8, 2012

Bristol Myers Squibb Co., of New York, will realize operating synergies and tax benefits in addition to gaining access to Amylin Pharmaceuticals Inc.'s GLP-1 franchise, executives said in a Monday morning conference call regarding the pharma giant's acquisition of San Diego-based Amylin and partnership agreement with AstraZeneca plc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription